Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Trevi Therapeutics, Inc. (NASDAQ:TRVI) has received an average rating of "Moderate Buy" from analysts, with nine firms contributing ratings including one sell, seven buy, and one strong buy.
• The average 1-year price objective for Trevi Therapeutics stock among brokers is $21.75, with price targets ranging from $18.00 to $25.00 by various firms.
• Trevi Therapeutics reported earnings of ($0.09) EPS, exceeding analysts' expectations, and anticipates a yearly EPS of -0.49 for the current fiscal year.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has received an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $21.75.

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Trevi Therapeutics in a research note on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price target on the stock. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Needham & Company LLC dropped their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Morgan Stanley began coverage on shares of Trevi Therapeutics in a report on Thursday, August 21st. They set an "overweight" rating and a $18.00 price objective on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Trevi Therapeutics in a report on Saturday, September 27th.

Institutional Trading of Trevi Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Trevi Therapeutics by 14.0% during the second quarter. China Universal Asset Management Co. Ltd. now owns 20,435 shares of the company's stock worth $112,000 after buying an additional 2,510 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in Trevi Therapeutics during the second quarter worth about $3,829,000. Rafferty Asset Management LLC purchased a new stake in Trevi Therapeutics during the second quarter worth about $60,000. Rubric Capital Management LP boosted its holdings in Trevi Therapeutics by 88.0% during the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company's stock worth $46,669,000 after buying an additional 3,993,325 shares in the last quarter. Finally, Octagon Capital Advisors LP boosted its holdings in Trevi Therapeutics by 10.5% during the second quarter. Octagon Capital Advisors LP now owns 3,672,000 shares of the company's stock worth $20,086,000 after buying an additional 350,000 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Up 3.3%

Shares of Trevi Therapeutics stock opened at $9.88 on Friday. Trevi Therapeutics has a 52-week low of $2.36 and a 52-week high of $9.99. The company's 50-day simple moving average is $7.91 and its 200-day simple moving average is $6.86. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -23.52 and a beta of 0.74.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Equities research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.